Compare Incyte Corporation (INCY) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Marathon Digital Holdings Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Marathon Digital Holdings Inc trades at $9.65 (market cap $3.83B). The key difference: Incyte Corporation is far larger — about 6× Marathon Digital Holdings Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Marathon Digital Holdings Inc for 22 Days on average.
| INCY | MARA | |
|---|---|---|
Market Cap | $22.85B | $3.83B |
Volume | 1,927,029 | 47,742,698 |
Sector | Health | Financials |
52-Week High | $129.93 | $22.84 |
52-Week Low | $83.80 | $6.73 |
Typical Hold Time | 33 Days | 22 Days |
Enterprise Value | $18.35B | $5.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
MARA stock trades at $9.91, down 4.34% today, showing bearish technical momentum despite recent volatility. The company faces significant fundamental challenges with a net income margin of -429.71% and consecutive quarterly earnings misses. Analyst sentiment remains divided with equal buy/hold ratings, while recent news highlights the stock's sensitivity to broader market movements and Bitcoin-related sector trends.
The outlook remains challenging due to persistent losses and negative profitability metrics. While the consensus price target of $13.25 suggests potential upside, investors face substantial execution risks amid heavy cash burn and competitive pressures in the technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
